Men at High Genetic Risk for Prostate Cancer identifier:
NCT03805919 (

Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Study Contact Information:

Anna Couvillon, Nurse Practitioner
By phone: (240) 858-3148
or by email 

About the Study

The National Cancer Institute opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. 

View the study on or contact Anna Couvillon, NP at: (240) 858-3148 or by email. 

What the Study Entails

Study Lead Investigator

Fatima Karzai, MD, National Cancer Institute (NCI)

Study Site

The National Institutes of Health (NIH), Clinical Center
Bethesda, MD in the Washington, DC metro area
NIH can cover the cost of travel for participants


This Study is Open To:

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.